Land: Irland
Språk: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
Doxylamine hydrogen succinate; Pyridoxine hydrochloride
Alliance Pharma (Ireland) Limited
R06AA59
Doxylamine hydrogen succinate; Pyridoxine hydrochloride
10/10 milligram(s)
Gastro-resistant tablet
doxylamine, combinations
Not marketed
2019-04-05
Xonvea PIL IE 002 PACKAGE LEAFLET: INFORMATION FOR THE USER XONVEA 10 MG/10 MG GASTRO-RESISTANT TABLETS doxylamine succinate/pyridoxine hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Xonvea is and what it is used for 2. What you need to know before you take Xonvea 3. How to take Xonvea 4. Possible side effects 5. How to store Xonvea 6. Contents of the pack and other information 1. WHAT XONVEA IS AND WHAT IT IS USED FOR WHAT XONVEA IS Xonvea contains two medicines (‘active substances’) called: ‘doxylamine succinate’ and ‘pyridoxine hydrochloride’. Doxylamine succinate belongs to a group of medicines called ‘antihistamines’. Pyridoxine hydrochloride is another name for Vitamin B 6 . WHAT XONVEA IS USED FOR Xonvea is used in pregnant women, to help stop them feeling sick (nausea) and being sick (vomiting). It is used when changes in diet or other non-medicine treatments have not worked. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE XONVEA DO NOT TAKE XONVEA IF: you are allergic to doxylamine succinate or other antihistamines (such as diphenhydramine), pyridoxine hydrochloride or any of the other ingredients of this medicine (listed in section 6) you are taking medicines for depression called ‘monoamine oxidase inhibitors’ (MAOIs) Do not take Xonvea if any of the above apply to you. If you are not sure, talk to your doctor, pharmacist or nurse before taking Xonvea. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist or nurse before Les hele dokumentet
Health Products Regulatory Authority 18 February 2020 CRN0094ZY Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Xonvea 10 mg/10 mg gastro-resistant tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gastro-resistant tablet contains 10 mg doxylamine succinate and 10 mg pyridoxine hydrochloride. Excipient(s) with known effect Each tablet contains trace amounts of azo colouring agent E129 For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Gastro-resistant tablet (tablet) White, round, film-coated tablet with a pink image of a pregnant woman on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Xonvea is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended starting dose is two tablets at bedtime (Day 1). If this dose adequately controls symptoms the next day, the patient can continue taking two tablets at bedtime. However, if symptoms persist into the afternoon of Day 2, the patient should continue the usual dose of two tablets at bedtime (Day 2) and on Day 3 take three tablets (one tablet in the morning and two tablets at bedtime). If these three tablets do not adequately control symptoms on Day 3, the patient can take four tablets starting on Day 4 (one tablet in the morning, one tablet mid-afternoon and two tablets at bedtime). The maximum recommended daily dose is four tablets (one in the morning, one in the mid-afternoon and two at bedtime). Xonvea should be taken as a daily prescription and not on an as needed basis. Continued need for Xonvea should be reassessed as the pregnancy progresses. To prevent a sudden return of nausea and vomiting of pregnancy symptoms, a gradual tapering dose of Xonvea is recommended at the time of discontinuation. Paediatric population Xonvea is not indicated for use in children under 18 years of age. The safety and efficacy of Xonvea has not been established in that population (see sec Les hele dokumentet